Key Takeaways Hesperos aims to accelerate the preclinical development of Psilera’s lead compound, PSIL-006, targeting frontotemporal dementia (FTD). Press Release “Our platform offers a unique opportunity to assess the compound’s effects on neural tissues derived from … Read More
